BR112022025933A2 - Compostos de ligação ao cereblon, composições dos mesmos e métodos de tratamento com os mesmos - Google Patents
Compostos de ligação ao cereblon, composições dos mesmos e métodos de tratamento com os mesmosInfo
- Publication number
- BR112022025933A2 BR112022025933A2 BR112022025933A BR112022025933A BR112022025933A2 BR 112022025933 A2 BR112022025933 A2 BR 112022025933A2 BR 112022025933 A BR112022025933 A BR 112022025933A BR 112022025933 A BR112022025933 A BR 112022025933A BR 112022025933 A2 BR112022025933 A2 BR 112022025933A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- cereblon
- binding compounds
- treatment methods
- methods
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- -1 Piperidinedione Compound Chemical class 0.000 abstract 1
- 102000001307 androgen receptors Human genes 0.000 abstract 1
- 108010080146 androgen receptors Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 150000005458 piperidinediones Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Cephalosporin Compounds (AREA)
- Medicinal Preparation (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063043555P | 2020-06-24 | 2020-06-24 | |
| PCT/US2021/038618 WO2021262810A1 (en) | 2020-06-24 | 2021-06-23 | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022025933A2 true BR112022025933A2 (pt) | 2023-01-10 |
Family
ID=79032408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022025933A BR112022025933A2 (pt) | 2020-06-24 | 2021-06-23 | Compostos de ligação ao cereblon, composições dos mesmos e métodos de tratamento com os mesmos |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US11634407B2 (enExample) |
| EP (1) | EP4171566A4 (enExample) |
| JP (2) | JP7781792B2 (enExample) |
| CN (2) | CN120441548A (enExample) |
| AR (1) | AR122723A1 (enExample) |
| AU (1) | AU2021296833A1 (enExample) |
| BR (1) | BR112022025933A2 (enExample) |
| CA (1) | CA3182325A1 (enExample) |
| CL (1) | CL2022003719A1 (enExample) |
| CO (1) | CO2022018653A2 (enExample) |
| IL (1) | IL299256A (enExample) |
| MX (1) | MX2022015757A (enExample) |
| PE (1) | PE20231746A1 (enExample) |
| SA (1) | SA522441857B1 (enExample) |
| TW (1) | TWI924678B (enExample) |
| WO (1) | WO2021262810A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021127443A1 (en) | 2019-12-19 | 2021-06-24 | Arvinas Operations, Inc. | Compounds and methods for the targeted degradation of androgen receptor |
| CN115996918A (zh) | 2020-05-09 | 2023-04-21 | 阿尔维纳斯运营股份有限公司 | 制造双官能团化合物的方法、双官能团化合物的超纯形式以及包括所述双官能团化合物的剂型 |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| IL299256A (en) | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
| ES3047718T3 (en) | 2020-06-24 | 2025-12-04 | Celgene Corp | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
| KR20240026939A (ko) * | 2021-06-25 | 2024-02-29 | 셀진 코포레이션 | 세레블론 결합 화합물, 이의 조성물, 및 이에 의한 치료 방법 |
| JP2025531869A (ja) | 2022-09-09 | 2025-09-25 | イノヴォ セラピューティクス、インコーポレイテッド | ＣＫ１αおよびＤＵＡＬ ＣＫ１α／ＧＳＰＴ１分解化合物 |
| AU2024344247A1 (en) | 2023-09-19 | 2026-05-07 | Kancure Pte. Ltd. | Survivin-targeted compounds |
| AU2024392985A1 (en) | 2023-12-08 | 2026-06-04 | Arvinas Operations, Inc. | Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy |
| WO2025179161A1 (en) | 2024-02-21 | 2025-08-28 | Innovo Therapeutics, Inc. | Protein degrading compounds |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101032483B (zh) * | 2006-03-09 | 2011-05-04 | 陈德桂 | 调节雄激素受体活性的乙内酰脲衍生物及其应用 |
| JP6817962B2 (ja) * | 2015-01-20 | 2021-01-20 | アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． | ターゲティングされたアンドロゲン受容体分解のための化合物および方法 |
| WO2017197046A1 (en) | 2016-05-10 | 2017-11-16 | C4 Therapeutics, Inc. | C3-carbon linked glutarimide degronimers for target protein degradation |
| CN110023297A (zh) * | 2016-07-08 | 2019-07-16 | 詹森药业有限公司 | 作为雄性激素受体拮抗剂的取代的乙内酰脲和硫代己内酰脲衍生物 |
| EP4717317A3 (en) | 2017-06-20 | 2026-06-03 | C4 Therapeutics, Inc. | N/o-linked degrons and degronimers for protein degradation |
| WO2020051260A1 (en) | 2018-09-05 | 2020-03-12 | University Of Tennessee Research Foundation | Selective androgen receptor degrader (sard) ligands and methods of use thereof |
| BR112021011968A2 (pt) | 2018-12-19 | 2021-09-08 | Celgene Corporation | Compostos de 3-((3-aminofenil)amino)piperidina-2,6-diona substituídos, composições dos mesmos e métodos de tratamento com os mesmos |
| AU2019404022A1 (en) | 2018-12-19 | 2021-07-08 | Celgene Corporation | Substituted 3-((3-aminophenyl)amino)piperidine-2,6-dione compounds, compositions thereof, and methods of treatment therewith |
| JP7778095B2 (ja) | 2020-06-24 | 2025-12-01 | セルジーン コーポレーション | セレブロン結合化合物、その組成物及びそれによる治療方法 |
| IL299256A (en) * | 2020-06-24 | 2023-02-01 | Celgene Corp | Cerebellum binding compounds, their compounds and methods of treatment with them |
| ES3047718T3 (en) | 2020-06-24 | 2025-12-04 | Celgene Corp | Cereblon binding compounds, compositions thereof, and methods of treatment therewith |
-
2021
- 2021-06-23 IL IL299256A patent/IL299256A/en unknown
- 2021-06-23 BR BR112022025933A patent/BR112022025933A2/pt unknown
- 2021-06-23 US US17/356,370 patent/US11634407B2/en active Active
- 2021-06-23 WO PCT/US2021/038618 patent/WO2021262810A1/en not_active Ceased
- 2021-06-23 PE PE2022003029A patent/PE20231746A1/es unknown
- 2021-06-23 MX MX2022015757A patent/MX2022015757A/es unknown
- 2021-06-23 CN CN202510574007.2A patent/CN120441548A/zh active Pending
- 2021-06-23 CA CA3182325A patent/CA3182325A1/en active Pending
- 2021-06-23 AR ARP210101735A patent/AR122723A1/es unknown
- 2021-06-23 CN CN202180044295.0A patent/CN115835866B/zh active Active
- 2021-06-23 JP JP2022580090A patent/JP7781792B2/ja active Active
- 2021-06-23 AU AU2021296833A patent/AU2021296833A1/en active Pending
- 2021-06-23 TW TW110122923A patent/TWI924678B/zh active
- 2021-06-23 EP EP21827824.0A patent/EP4171566A4/en active Pending
-
2022
- 2022-12-22 SA SA522441857A patent/SA522441857B1/ar unknown
- 2022-12-22 CO CONC2022/0018653A patent/CO2022018653A2/es unknown
- 2022-12-22 CL CL2022003719A patent/CL2022003719A1/es unknown
-
2023
- 2023-03-16 US US18/122,496 patent/US12103920B2/en active Active
-
2024
- 2024-07-18 US US18/776,606 patent/US20250188056A1/en active Pending
-
2025
- 2025-11-26 JP JP2025203650A patent/JP2026035702A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US11634407B2 (en) | 2023-04-25 |
| KR20230027066A (ko) | 2023-02-27 |
| CO2022018653A2 (es) | 2023-03-27 |
| MX2022015757A (es) | 2023-01-19 |
| JP2023533203A (ja) | 2023-08-02 |
| JP2026035702A (ja) | 2026-03-04 |
| CA3182325A1 (en) | 2021-12-30 |
| SA522441857B1 (ar) | 2024-07-21 |
| EP4171566A1 (en) | 2023-05-03 |
| WO2021262810A1 (en) | 2021-12-30 |
| TW202216680A (zh) | 2022-05-01 |
| PE20231746A1 (es) | 2023-11-06 |
| US20210403454A1 (en) | 2021-12-30 |
| CL2022003719A1 (es) | 2023-05-12 |
| US20250188056A1 (en) | 2025-06-12 |
| JP7781792B2 (ja) | 2025-12-08 |
| EP4171566A4 (en) | 2024-07-24 |
| CN120441548A (zh) | 2025-08-08 |
| AR122723A1 (es) | 2022-09-28 |
| CN115835866B (zh) | 2025-05-02 |
| US20230242509A1 (en) | 2023-08-03 |
| CN115835866A (zh) | 2023-03-21 |
| AU2021296833A1 (en) | 2023-01-19 |
| TWI924678B (zh) | 2026-05-11 |
| IL299256A (en) | 2023-02-01 |
| US12103920B2 (en) | 2024-10-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022758A2 (pt) | Compostos de 1-oxo-isoindolina-5-carboxamida substituídos, suas composições e métodos de tratamento com os mesmos | |
| SA522441857B1 (ar) | مركبات ربط سيريبلون، توليفات منها، وطرق للمعالجة باستخدامها | |
| CO2021007973A2 (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y métodos de tratamiento con estos | |
| BR112023021068A2 (pt) | Compostos, composições e métodos para tratar câncer | |
| BR112021006229A2 (pt) | composto, composição farmacêutica, e, método para tratamento de um câncer | |
| BR112015022462A8 (pt) | inibidores de ido, composição farmacêutica, método de inibição de atividade de indolamina 2,3-dioxigenase e uso dos referidos inibidores | |
| CO2019003482A2 (es) | Compuestos derivados de ciclobutano o azetidina 1,3 disustituidos como inhibidores de la prostaglandina d sintasa hematopoyética | |
| BR112023023578A2 (pt) | Composto, composição farmacêutica compreendendo o composto e método de tratamento de uma leucemia aguda | |
| BR112022001324A2 (pt) | Composto, composição farmacêutica e método para tratamento de uma doença mediada por p38 map quinase em um indivíduo necessitando do mesmo | |
| MX2021007475A (es) | Compuestos de 3-((3-aminofenil)amino)piperidina-2,6-diona sustituida, composiciones de estos y metodos de tratamiento con estos. | |
| BR112012021659A2 (pt) | composto, composição farmacêutica, método para tratar e/ou prevenir distúrbios e doenças. | |
| BR112016002638A2 (pt) | novos aza-oxo-indóis para o tratamento e profilaxia de infecção pelo virus sincicial respiratório | |
| BR112022015792A2 (pt) | Inibidores de pad4 heterocíclicos | |
| EA202190272A1 (ru) | Дополнительно замещенные производные триазолохиноксалина | |
| BR112022001025A2 (pt) | Inibidores de calicreína plasmática | |
| BR112022001390A2 (pt) | Inibidores de enzima | |
| EA202190271A1 (ru) | Замещенные триазолохиноксалиновые производные | |
| BR112012013918A2 (pt) | inibidores de diacil glicerol acil transferase | |
| BR112021025618A2 (pt) | Composto, método para prevenir, tratar ou diminuir a gravidade de uma doença, composição farmacêutica e uso de um composto | |
| BR112017025189A2 (en) | composition and uses thereof | |
| BR112021022270A2 (pt) | Materiais e métodos para tratar degeneração macular relacionada à idade | |
| BR112022018793A2 (pt) | Uso de um composto de fórmula (i) ou (ii) para tratar ou previnir uma infecção por coronaviridae e condições relacionadas, composição farmacêutica e medicamento compreendendo os mesmos, uso de um mirna como um biomarcador de uma infecção por coronaviridae, e método para avaliar uma infecção por coronaviridae | |
| BR112022021391A2 (pt) | N-fenilacetamidas substituídas que possuem atividade antagonista a receptor de p2x4 | |
| BR112023001325A2 (pt) | Composto, composição farmacêutica, e, métodos para tratar uma doença causada por um vírus, para inibir a endonuclease dependente de cápsula, para tratar influenza em um mamífero e para prevenir influenza em um mamífero | |
| BR112023021790A2 (pt) | Composto de fórmula (i); composto selecionado; processo para preparação de compostos de fórmula (i); composição farmacêutica; método para o tratamento e/ou prevenção de uma condição mediada por pd-1/pd-l1 ou um distúrbio proliferativo ou câncer; método para o tratamento ou prevenção de doença ou distúrbio proliferativo ou câncer; uso dos compostos; e; método para o tratamento de câncer |